Last reviewed · How we verify
Docetaxel combined + Trastuzumab +Pertuzumab
This combination uses a microtubule-stabilizing chemotherapy agent (docetaxel) together with two HER2-targeting monoclonal antibodies (trastuzumab and pertuzumab) to inhibit HER2-driven cancer cell growth through multiple mechanisms.
This combination uses a microtubule-stabilizing chemotherapy agent (docetaxel) together with two HER2-targeting monoclonal antibodies (trastuzumab and pertuzumab) to inhibit HER2-driven cancer cell growth through multiple mechanisms. Used for HER2-positive metastatic breast cancer, HER2-positive gastric cancer (potential).
At a glance
| Generic name | Docetaxel combined + Trastuzumab +Pertuzumab |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
| Drug class | Chemotherapy + HER2-targeted monoclonal antibody combination |
| Target | HER2 (trastuzumab and pertuzumab); microtubule stabilization (docetaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel stabilizes microtubules and prevents cell division. Trastuzumab binds HER2 and blocks its signaling while recruiting immune cells to kill cancer cells. Pertuzumab binds a different epitope on HER2 and prevents HER2 dimerization with other receptors. Together, this triple combination provides synergistic anti-tumor activity in HER2-positive cancers.
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive gastric cancer (potential)
Common side effects
- Neutropenia
- Anemia
- Nausea/vomiting
- Diarrhea
- Peripheral neuropathy
- Fatigue
- Cardiac dysfunction (HER2-targeted)
- Infusion reactions
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (PHASE2)
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (PHASE3)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: